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Abstract
Background: Assessing effectiveness of the next generation probiotic Ferzym in conjunction with other probiotics for correction of the microbiocenotic 
status in different digestive disorders.
Material and methods: 120 children aged between 6 months and 17 years, with the mean age of 9.3 ± 0.61 years, were included in the study, being 
admitted to Gastroenterology Department of Institute of Mother and Child.  The research methods included: thorough anamnesis of the disease and 
comprehensive clinical examination.  The clinical testing procedure included a clinical monitoring during the 10-day inpatient treatment and 1 month 
after the outpatient treatment.
Results: A more favorable clinical and progressive improvement curve was observed in children who received Ferzym. Both the stool consistency 
and frequency improved faster. It has been recorded a gradual and continuous remission of the abdominal pain and decrease of the discomfort up to the 
10th day of treatment.  The final segment of the “treatment with probiotics” curve confirms the assumption that treatment effectiveness is maintained for 
about 10 days, so that it can cover the acute period of disturbances.
Conclusions: Ferzym is practically the only solution in the intestinal microbiocenosis control in children with intestinal malabsorption and Coeliac 
disease, as the capsule does not contain dismulate gluten. Efficacy of Ferzym indicated to children with digestive disorders is a priority over the biological 
non-sorbit preparations and monocompetent ones because Ferzym regulates the microbiocenotic status of the small intestine and colon.
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Introduction
Intestinal microflora plays an indispensable role in restor-
ing the vitamin and fermentation balance, in building unspe-
cific resistance, as well as in other important functions such 
as trophic and energetic functions, functions of stimulating 
intestinal peristalsis, of detoxification, endotoxin and exotoxin 
evacuation, mutagen elimination etc. [1, 2, 3].  A wide variety 
of biological preparations can be used for restoring the balance 
of the intestinal flora, but their recommendation should be 
based upon a well-balanced decision and the clinical benefit 
for the patient, especially in case of children [1, 3, 5, 6].  Pro-
biotics, remedies that contain live bacteria ready to colonise 
the intestinal tract, represent the most significant group of 
biological preparations [2, 4, 7, 8, 13].
In 2001, the World Health Organization defined probiotics 
as “live microorganisms which when administered in adequate 
amounts confer a health benefit to the host.”  Despite their 
beneficial effect in the host, these preparations require special 
storage conditions, otherwise they can turn unstable and, 
eventually, ineffective [10, 13].  Moreover, in order to be able 
to colonise the intestinal tract, several conditions should be 
met (for example, intestinal pH etc.), which frequently lack 
in children with digestive disorders [2, 12, 13].  The majority 
of biological remedies available today are monocomponent 
preparations, i.e. they contain only one microorganism – a 
situation which cannot restore the state of microbiocenosis 
neither of the large intestine nor of the small one [9, 10, 11]. 
Having considered the advantages of the probiotic prepara-
tions for the correction of the microbiocenosis state in various 
digestive disorders, we have selected Ferzym.
Ferzym is a polycomponent supplement that contains 
strains of Bifidobacterium microorganism subsp.  Lactis 
BLC1, Lactobaciluus acidophilus LA3, Bacillus coagulans 
BC513 and a number of vitamins indispensable for the human 
body (vitamin B1, B2, niacine, panthothenic acid, vitamin 
B6, folic acid, vitamin B12), thus having the mechanism of 
redressing the microbiocenosis state of the small intestine and 
colon.  Ferzym is available in enteric-coated capsules, which 
are freed intact in the intestine where they dissolve in pH 6.8. 
Ferzym is an oral preparation from a new group of probiotics 
which, besides live bacteria, also contains in its capsule the 
culture environment of the microorganisms, which increases 
the bacteria survival rate and optimum colonisation of the 
intestinal tract.
In comparison with other probiotic preparations, Ferzym 
capsule is gluten free, which represents an advantage for 
children who suffer from intestinal malabsorption, especially 
children with Coeliac disease.
The purpose of the study was to evaluate the effectiveness 
of Ferzym administration in the treatment of digestive dis-
eases in children with gluten and lactose intolerance, coeliac 
disease, intestinal malabsorption and pathogenic microflora 
growth, bacterial contamination of the colon, irritable bowel 
syndrome, as well as antibiotic-associated diarrhoea.
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Material and methods
The study was a prospective case-control one.  Object 
of study: 120 children aged between 6 months and 17 years, 
from the Gastroenterology unit, Public Medical-Sanitary 
Institution: Institute for Mother and Child Health Care.  The 
average age of the children included in the study constituted 
9.3 ± 0.61 years, among them 23.4% (28 patients) children 
under the age of 2, 50% (60 patients) – children aged between 
2 and 12 years, and 26.7% (32 patients) – children older than 
12 years (fig. 1).
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Fig. 1.  Distribution of children by age group.
The patients were selected based on the assessment of their 
complaints, anamnesis data of their life and health condition, 
as well as parents’ (guardians’) informed consent to the aim 
and the methodology of preparation administration.
Children with allergic reactions as well as children whose 
parents did not give their consent were excluded from the 
study.
The methods of research included: detailed anamnestic 
method in studying morbidity and thorough clinical exami-
nation.  The clinical trial included a 10-day inpatient moni-
toring as well as one month outpatient monitoring, namely 
the monitoring of patient’s general condition, evaluation of 
the abdominal pains, frequency and consistency of the stool, 
meteorism.
The Instrumental and Laboratory Examinations included 
blood count test, urine test; stool ova and parasite examina-
tion; examination of the intestinal microbiocenosis; biochemi-
cal tests (total and indirect bilirubin levels, ALT, AST, urea, 
creatine, amylase, glycemic index, calcemia, phosphatemia, 
sideremy), ultrasound examination, radiological examination, 
endoscopy and histology.
Children with intestinal malabsorption from the control 
group did not receive probiotics, because these preparations 
contain (dismulate) gluten.
The clinical test of the preparation was conducted by 
comparison with the curative care programs recommended 
for children with the same diagnosis.
Considering that gastric acidity is relatively low in children 
under the age of 2, the patients from this group received un-
encapsulated Ferzym.  Thus, children aged between 6 months 
and 5 years received 0.5 capsules twice a day, children aged 
between 6 and 14 years received 1 capsule twice a day, while 
children older than 14 years received 1-3 capsules twice a day.
All the children included in the study (from both groups) 
followed a gluten and lactose free diet.  They have also received 
all the necessary medication recommended for digestive 
disorders.
The statistical analysis applied the χ2 criterion, the Fisher 
criterion, Student t-criterion and the correlation coefficient for 
parametric and nonparametric indices.  The statistical veracity 
was performed for each result and the p-value beyond 0.05 
level was considered as significant one.
Results
The clinical monitoring of the general health condition 
of the children included in the study helped determine com-
paratively the stool frequency and consistency, the type and 
period of reduction of the meteorism and abdominal pains, 
microbiocenosis deviations.
One of the aims of the study was to observe the regression 
of the stool frequency in children who received Ferzym, com-
pared to the indices of the children who received a non-sorbed 
monocompetent probiotic (fig. 2).  It is necessary to mention 
that the absolute number shows the improvement of the stool 
but not its reduction or the reduction of its frequency and, 
respectively, it shows the presence of daily stools in constipated 
children or the reduction of the stool frequency in children 
with diarrhoea, during the 10-day treatment.
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Fig. 2.  Comparative evolution of stool frequency after Ferzym 
administration, compared to stool frequency in children who 
received a non-sorbed monocomponent probiotic.
The findings show that children who received Ferzym 
showed a better improvement of the stool frequency.  More-
over, the curve is a progressive one, showing increased im-
provement in the stool of children who received Ferzym (p = 
0.0487) in comparison with children who received probiotics 
from other groups.  The same progressive direction is seen in 
the curve showing the stool consistency in children following 
the curative care supplemented by Ferzym (fig. 3), in com-
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parison with the reference value (p = 0.05).  All the children 
who received Ferzym showed considerable improvements.
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Fig. 3.  Comparative evolution of stool consistency after Ferzym 
administration, compared to stool consistency in children who 
received a non-sorbed monocomponent probiotic.
The improvement curves representing meteorism show a 
definite effectiveness of Ferzym administration in the treat-
ment of digestive disorders (fig. 4), in comparison with the 
administration of non-sorbit monocomponent probiotics.  In 
conclusion, the deviation between the improvement value in 
the group of children with malabsorption and Coeliac disease, 
who received Ferzym, and those who followed the gluten-free 
diet, was due exclusively to Ferzym administration.  Thus, if 
comparing the outcomes of all children under study, where 
the rate of children with intestinal malabsorption, Coeliac 
disease and lactose intolerance constituted approximately 63% 
(29 children), then the improvement deviation between the 
control groups constituted approximately 26% (12 children), 
showing better results in children who received Ferzym.
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Fig. 4.  Comparative evolution of abdominal meteorism after 
Ferzym administration.
The general condition improvement and abdominal pains 
reduction were progressively recorded until the 10th day of the 
treatment (fig. 5).  The last segment of the curve “treatment 
with probiotics” confirms the supposition that the effective-
ness of the treatment is maintained for 10 days, thus it can 
cover the acute period of the disorder.
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Fig. 5.  Comparative evolution of discomfort or abdominal pain 
after Ferzym administration.
Including Ferzym in the treatment of children with diges-
tive disorders, especially children with intestinal malabsorp-
tion, Coeliac disease, certainly improves the general health 
condition of the patients.  Ferzym is practically the only 
solution to restore the intestinal microbiocenosis in children 
suffering from intestinal malabsorption and Coeliac disease, 
due to the fact that its capsule does not contain gluten.  The 
improvements recorded in children with intestinal malab-
sorption from the control group were attributed to the strict 
following of the gluten-free regimen.  The values of the Ferzym 
curve show the real contribution of the probiotics adminis-
tration in the improvement of the clinical condition in the 
above mentioned diseases, especially in the case of intestinal 
malabsorption and lactose intolerance.
Accordingly, we can draw the conclusion that from all 
the clinical symptoms the most responsive proved to be the 
abdominal meteorism, a condition that considerably improves 
the quality of children’s life, especially of children suffering 
from intestinal malabsorption, Coeliac disease, and lactose 
intolerance.  This condition is followed by the reduction of ab-
dominal pains, the significance of which is evident in children 
suffering from any disease.  After Ferzym administration clear 
improvements were recorded in other symptoms and signs as 
well: in the stool consistency and frequency, symptoms which 
actually represent the criteria for evaluation of the clinical 
condition in the diseases under study.
We consider that reduction of the abdominal pains in chil-
dren with irritable bowel syndrome was recorded not because 
of the analgesic or spasmolytic effect of the preparation, but 
mainly because of the meteorism reduction.  This is because 
children with irritable bowel syndrome have an increased 
intestinal sensitivity, which means that excitations, which are 
considered physiological (such as intestinal meteorism, in this 
case), represent a negative factor for them.  The improvement 
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of the clinical condition of children with this diagnosis, includ-
ing abdominalgia, is a timely and important finding, because 
a single remedy can cure a series of essential clinical signs.
After having processed the indices of the microbiocenosis 
state in children before and after the treatment, the findings 
showed that of 32 children with 3rd degree disorder before the 
treatment, only 9 still had it after the treatment with Ferzym 
(fig. 6), which accounts for a 70% reduction (p < 0.08; x² 
= 3.0).  This is an encouraging result which leads us to the 
conclusion that the administration of gluten-free capsules can 
be recommended to children with Coeliac disease, intestinal 
malabsorption, ulcerative colitis and other digestive diseases.
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Fig. 6.  Level of modification of the intestinal microbiocenosis 
state in children before and after the treatment with Ferzym.
It is worth mentioning that during the 10-day inpatient 
treatment, the daily monitoring of the clinical condition of 
children under study did not record any cases of immediate 
or late-phase allergic reactions.
Concomitant administration of Ferzym with Amoxicillin, 
Ampicillin, Clarithromycin, Metronidazole, Cefazolin, Ceftri-
axon does not modify the effectiveness of the probiotic.  The 
improvement of the condition in cases of increased growth 
of the pathogenic bacteria in intestinal microflora and colon 
colonisation by bacteria is evident, especially in comparison 
with children whose treatment was not supplemented with 
probiotics.  Moreover, we have also observed that the shorter 
the interval between the antibiotic therapy and the initiation 
of the treatment with Ferzym, the more evident its effective-
ness.  The treatment with Ferzym should be extended for at 
least 3 weeks, in case there was a longer period of time after 
the interruption of the antibiotic therapy, irrespective of the 
reasons of the time lag.
Conclusions
1. The effectiveness of Ferzym administration in children 
with digestive diseases proved to be higher compared to 
non-sorbed biological preparations or monocompetent ones, 
because Ferzym restores the microbiocenosis of the small 
intestine and colon.
2. The administration of Ferzym in children with intestinal 
malabsorption, including children with Coeliac disease, has 
recorded a favourable evolution of the health condition, due 
to the fact that its capsule does not contain gluten.
3. Including Ferzym at an early stage of the treatment has 
a direct relation with its effectiveness.  Thus, a long time lag 
after the interruption of the antibiotic therapy and Ferzym 
administration leads to the extension of the treatment for at 
least 3 weeks.
4. Ferzym proved to be efficient in the treatment of func-
tional disorders of the intestine, accompanied by constipa-
tion and diarrhoea, due to the fact that it eliminates one of 
the pathogenic causes of these disorders – microbiocenosis 
disbalance.
5. The administration of un-encapsulated form of Ferzym 
in children under the age of 2 does not reduce the effectiveness 
of the remedy and does not generate adverse effects.
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